Cell Based Therapy for Corneal Endothelial Regeneration
Cell based therapy, as an alternative to conventional donor corneal transplantation, is anticipated to provide a less invasive and more effective therapeutic modality for corneal endothelial dysfunction. The proliferative capability of human corneal endothelial cells is severely controlled, thus making the establishment of optimal conditions for the cultivation of human corneal endothelial cells a critical aspect for the clinical application of a cell based therapy. Recently, successful cultivation protocol of human corneal endothelial cells for clinical application which includes the use of Rho kinase (ROCK) inhibitor and the inhibition of transforming growth factor beta signaling were reported to promote the cell proliferation and to support human corneal endothelial cell cultures that show high cell density. Animal experiments showed that a cell-injection therapy combined with the use of a ROCK inhibitor promotes cultivated corneal endothelial cell adhesion onto the posterior cornea, ultimately resulting in the recovery of corneal transparency. A pilot clinical study was recently initiated in Japan to investigate the efficacy of a cell-injection therapy for patients with bullous keratopathy.
KeywordsCorneal endothelium Bullous keratopathy Cell based therapy Cell-injection therapy Rho kinase inhibitor
Conflict of Interest
Noriko Koizumi and Naoki Okumura declare that they have no conflict of interest.” (If any authors do have a conflict of interest it must be spelled out specifically).
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
No animal studies were carried out by the authors for this article.
- 40.Okumura N, Kinoshita S, Koizumi N. Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases. J Ophthalmol. 2017;2017:2646904.Google Scholar